Forest Laboratories has entered into a definitive m&a deal to acquire Aptalis for $2.9 billion in cash from its shareholders.
The m&a deal, which requires review by anti-trust authorities in the US and Canada, is expected to be accretive to Forest’s FY2015 non-GAAP EPS.
Forest intends to acquire Aptalis from its shareholders for $2.9 billion in cash.
Forest expects to use a combination of cash on hand and debt to fund the transaction.
Forest has secured commitment for a $1.9 billion bridge facility.
View the full article at Reuters
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity